Literature DB >> 31962292

Study of the intestinal uptake and permeability of gold nanoparticles using both in vitro and in vivo approaches.

Maria Enea1, Eulália Pereira, Diana Dias Silva, Joana Costa, Maria Elisa Soares, Maria de Lourdes Bastos, Helena Carmo.   

Abstract

Gold nanoparticles (AuNPs) are highly attractive to biomedical applications. Here, we investigated the effects of (i) ca. 15 nm spherical AuNPs capped with citrate or 11-mercaptoundecanoic acid (MUA) and (ii) ca. 60 nm spherical citrate-capped AuNPs, and ca. 60 nm MUA-capped star-shaped AuNPs on the cytotoxicity, cellular uptake and permeability, using media supplemented or not with 1% fetal bovine serum (FBS) on caucasian colon adenocarcinoma Caco-2 cells. In addition, the colloidal stability of the nanoparticles in media (supplemented or not) was assessed after 24 h-incubations at 60 μM. The 60 nm gold nanospheres and stars were administrated orally to Wistar rats in order to evaluate their systemic absorption and biodistribution after 24 h. At non-supplemented media settings, citrate-capped gold nanoparticles seem to be more toxic than their MUA-capped counterparts. Also, smaller nanoparticles show higher toxicity than larger ones. The use of cell culture media with 1% FBS not only increased the stability of all AuNPs, as also significantly reduced their cytotoxicity. In the uptake studies, higher AuNPs incorporation was noticed in serum supplemented media, this effect being particularly significant for the 60 nm nanoparticles. Cellular incorporation depended also on the capping agent and size. None of the tested samples crossed the in vitro intestinal barrier. Confirming the in vitro results, the in vivo biodistribution study of the 60 nm AuNPs orally given to rats showed that their systemic absorption is low and that they are mainly eliminated through the faeces. Altogether, these preliminary results suggest that our novel AuNPs have high potential to be considered promising candidates for application in diagnostics or drug delivery at the intestinal level, showing high biocompatibility. However, unless it is desired that these nanomaterials avoid systemic absorption upon oral administration, additional functionalization should be sought to increase their low bioavailability.

Entities:  

Year:  2020        PMID: 31962292     DOI: 10.1088/1361-6528/ab6dfb

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  5 in total

Review 1.  Multifunctional Gold Nanoparticles in Cancer Diagnosis and Treatment.

Authors:  Yan Yang; Xi Zheng; Lu Chen; Xuefeng Gong; Hao Yang; Xingmei Duan; Yuxuan Zhu
Journal:  Int J Nanomedicine       Date:  2022-05-06

2.  Nano-Hybrid Au@LCCs Systems Displaying Anti-Inflammatory Activity.

Authors:  Marcello Condorelli; Antonio Speciale; Francesco Cimino; Claudia Muscarà; Enza Fazio; Luisa D'Urso; Carmelo Corsaro; Giulia Neri; Angela Maria Mezzasalma; Giuseppe Compagnini; Fortunato Neri; Antonina Saija
Journal:  Materials (Basel)       Date:  2022-05-22       Impact factor: 3.748

3.  Gold Nanoparticles Induce Oxidative Stress and Apoptosis in Human Kidney Cells.

Authors:  Maria Enea; Eulália Pereira; Miguel Peixoto de Almeida; Ana Margarida Araújo; Maria de Lourdes Bastos; Helena Carmo
Journal:  Nanomaterials (Basel)       Date:  2020-05-22       Impact factor: 5.076

4.  Atropine-functionalized gold nanoparticles binding to muscarinic receptors after passage across the intestinal epithelium.

Authors:  Rebecca Claßen; Ervice Pouokam; Matthias Wickleder; Martin Diener; Annabelle Mattern
Journal:  R Soc Open Sci       Date:  2022-10-05       Impact factor: 3.653

5.  Influence of Physicochemical Characteristics and Stability of Gold and Silver Nanoparticles on Biological Effects and Translocation across an Intestinal Barrier-A Case Study from In Vitro to In Silico.

Authors:  Yvonne Kohl; Michelle Hesler; Roland Drexel; Lukas Kovar; Stephan Dähnhardt-Pfeiffer; Dominik Selzer; Sylvia Wagner; Thorsten Lehr; Hagen von Briesen; Florian Meier
Journal:  Nanomaterials (Basel)       Date:  2021-05-21       Impact factor: 5.076

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.